SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Effective after trading hours on January 3, 2017, Second Sight
Medical Products, Inc. (the Company) granted options to certain
employees and officers to the Second Sight Medical Products, Inc.
2011 Equity Incentive Plan. The following officers of the Company
were awarded options:
| Name | Title | Amount | ||||
| Robert Greenberg, M.D., Ph.D. | Chairman | 256,410 | ||||
| Will McGuire | President and Chief Executive Officer | 571,330 | ||||
| Thomas Miller | Chief Financial Officer | 181,980 | ||||
| Steve Okland | Commercial Vice President, U.S. and Canada | 220,840 | ||||
| Edward Randolph | Vice President of Manufacturing | 151,170 | ||||
| Gregoire Cosendai | Vice President of European Operations | 228,190 | ||||
The options have a strike price of $1.97 per share, which was the
closing price of Companys shares on the effective date of grant.
The options vest over a four year term of which one-fourth vests
on the one year anniversary of the date of grant, with the
remaining options vesting quarterly over three years thereafter.
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina. SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Recent Trading Information
SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) closed its last trading session down -0.03 at 1.99 with 170,422 shares trading hands.
